open access

Vol 15, No 1 (2020)
Review Papers
Published online: 2020-02-27
Get Citation

A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC

Agnieszka Bureta, Bartosz Kwiatkowski, Małgorzata Lelonek
DOI: 10.5603/FC.2020.0005
·
Folia Cardiologica 2020;15(1):19-26.

open access

Vol 15, No 1 (2020)
Review Papers
Published online: 2020-02-27

Abstract

Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.

Abstract

Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.

Get Citation

Keywords

cancer, anticoagulant treatment, non-vitamin K antagonist oral anticoagulants

About this article
Title

A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC

Journal

Folia Cardiologica

Issue

Vol 15, No 1 (2020)

Pages

19-26

Published online

2020-02-27

DOI

10.5603/FC.2020.0005

Bibliographic record

Folia Cardiologica 2020;15(1):19-26.

Keywords

cancer
anticoagulant treatment
non-vitamin K antagonist oral anticoagulants

Authors

Agnieszka Bureta
Bartosz Kwiatkowski
Małgorzata Lelonek

References (35)
  1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A. ed. Clinique Medicale de l’Hotel Dieu de Paris. Balllier, Paris 1865: 654–712.
  2. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007; 62(2): 126–136.
  3. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980; 73(7): 841–843.
  4. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005; 165(15): 1782–1787.
  5. Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer. 2006; 106(4): 923–930.
  6. Rance A, Emmerich J, Guedj C, et al. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet. 1997; 350(9089): 1448–1449.
  7. Sutherland DE, Weitz IC, Liebman HA, et al. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003; 72(1): 43–52.
  8. Lee AYY, Lee A. Epidemiology and management of venous thromboembolism in patients with cancer. Thrombosis Research. 2003; 110(4): 167–172.
  9. Larsen TB, Nielsen PB, Skjøth F, et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One. 2014; 9(12): e114445.
  10. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators, EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
  11. Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
  12. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342–2352.
  13. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
  14. Zhang J, Xu J, Zhang W, et al. Quality appraisal of guidelines on cancer-associated thrombosis using AGREE II instrument and analysis of current status of new oral anticoagulants. Clin Appl Thromb Hemost. 2019; 25: 1076029619846562.
  15. Prandoni P, Lensing A, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484–3488.
  16. Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–153.
  17. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119(12): 1062–1072.
  18. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II); 53rd ASH Annual Meeting and Exposition. San Diego, December 10–13, 2011.
  19. Lee AYY, Kamphuisen PW, Meyer G, et al. CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015; 314(7): 677–686.
  20. Raskob GE, van Es N, Segers A, et al. Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016; 3(8): e379–e387.
  21. Raskob GE, van Es N, Verhamme P, et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
  22. CASTA-DIVA. ClinicalTrials.gov Identifier: NCT02746185. https://clinicaltrials.gov/ct2/show/NCT02746185 (January 31, 2018).
  23. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients With cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
  24. Deitcher SR, Kessler CM, Merli G, et al. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12(4): 389–396.
  25. Carrier M, Abou-Nassar K, Mallick R, et al. AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019; 380(8): 711–719.
  26. Khorana AA, Soff GA, Kakkar AK, et al. CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019; 380(8): 720–728.
  27. Gajewski P, Szczeklik A. ed. Interna Szczeklika. Ed. 9. Medycyna Praktyczna, Kraków 2018.
  28. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017; 6(6): 1165–1172.
  29. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014; 134(6): 1198–1204.
  30. Lindahl TL, Wallstedt M, Gustafsson KM, et al. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res. 2015; 135(3): 544–547.
  31. Eikelboom JW, van Ryn J, Reilly P, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373(6): 511–520.
  32. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124(14): 1573–1579.
  33. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015; 131(1): 82–90.
  34. Portola Pharmaceuticals. US FDA approves Portola Pharmaceuticals’ Andexxa, first and only antidote for the reversal of factor Xa inhibitors. Published on: May 3, 2018. Accessed on: May 4, 2018.
  35. Peterson EA, Lee AYY, Lee AYY, et al. Treatment of cancer-associated thrombosis. Blood. 2013; 122(14): 2310–2317.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl